Arachidonoyl 2'-fluoroethylamide
Arachidonoyl 2'-fluoroethylamide is an anandamide analog. Arachidonoyl 2'-fluoroethylamide has the potential for the research of intraocular hypertension.
For research use only. We do not sell to patients.
- CAS No.: 166100-37-4
- Formula: C22H36FNO
- Molecular Weight:349.53
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-W009123
ErucamideTMEM19 Ligand, T3SS Inhibitor -
HY-157833
Heptadecanoyl ethanolamideEndogenous Cannabinoid -
HY-126720
N-Lignoceroyl Taurine -
HY-134110
N-Methylarachidonamide -
HY-120962
N-Arachidonoyl TaurineTRPV Activator -
HY-124001
N-Docosanoyl taurineLipoamino Acids -
HY-120969
Docosanoyl ethanolamideEster Product -
HY-139132
Met-F-AEAAntitumor Agent -
HY-134615
Mead ethanolamideCB1/CB2 Agonist -
HY-121975
N-CyclohexanecarbonylpentadecylamineNAAA Inhibitor -
HY-124089S
Eicosapentaenoyl ethanolamide-d4Stable Isotope -
HY-69262
2-(Hexadecyloxy)-1,3-propanediolEster Product
Biological Activity
Description
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:2.6-3.6 kg normotensive pigmented rabbit[1]
-
Dosage:25 µl (0.25% (w/v))
-
Administration:Unilateral ocular administration
-
Result:Induced IOP (intraocular pressure) in the treated eye initially increased and then decreased.
Chemical Information
-
CAS No. 166100-37-4
-
Molecular Weight 349.53
-
Formula C22H36FNO
-
SMILES
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(NCCF)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Arachidonoyl 2'-fluoroethylamide Related Classifications
HY-134224 Related Classifications
Powered by Bioz